

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/340521176>

# Effectiveness of body roundness index in predicting metabolic syndrome: A systematic review and meta-analysis

Article in *Obesity Reviews* · April 2020

DOI: 10.1111/obr.13023

CITATIONS

95

READS

500

6 authors, including:



**Sergio Rico Martin**

Universidad de Extremadura

71 PUBLICATIONS 524 CITATIONS

[SEE PROFILE](#)



**Julian F Calderon-Garcia**

Universidad de Extremadura

67 PUBLICATIONS 490 CITATIONS

[SEE PROFILE](#)



**Cristina Franco-Antonio**

Universidad de Extremadura

24 PUBLICATIONS 214 CITATIONS

[SEE PROFILE](#)



**Mariana Martínez Álvarez**

Universidad de Extremadura

28 PUBLICATIONS 184 CITATIONS

[SEE PROFILE](#)

# Effectiveness of body roundness index in predicting metabolic syndrome: A systematic review and meta-analysis

Sergio Rico-Martín<sup>1</sup>  | Julián F. Calderón-García<sup>1</sup> | Purificación Sánchez-Rey<sup>1</sup> |  
Cristina Franco-Antonio<sup>1</sup> | Mariana Martínez Alvarez<sup>2</sup> | Juan F. Sánchez Muñoz-Torrero<sup>3</sup>

<sup>1</sup>Department of Nursing, Nursing and Occupational Therapy College, University of Extremadura, Cáceres, Spain

<sup>2</sup>Department of Nursing, Faculty of Medicine, University of Extremadura, Badajoz, Spain

<sup>3</sup>Department of Internal Medicine, Hospital Universitario de Cáceres, Cáceres, Spain

## Correspondence

Sergio Rico-Martín. Facultad de Enfermería y Terapia Ocupacional de Cáceres, Universidad de Extremadura, Avd. La Universidad, 10003 Cáceres, Spain.

Email: [sergiorico@unex.es](mailto:sergiorico@unex.es)

## Summary

Body roundness index (BRI) is a new anthropometric index developed to predict both body fat and the percentage of visceral adipose tissue. Our aim was to investigate whether BRI is superior to traditional anthropometric indices in predicting metabolic syndrome (MetS). This systematic review and meta-analysis was conducted using Pubmed, Scopus and Web of Sciences databases. The estimated pooled areas under curve (AUCs) for BRI predicting MetS was higher than body mass index (BMI), waist-to-hip ratio (WHR), body shape index (ABSI) and body adiposity index (BAI), similar to waist circumference (WC) and lower than waist-to-height ratio (WHtR). However, the difference between BRI and BMI, WC and WHtR predicting MetS was statistically non-significant. Similar results were found with the summary receiver operating characteristic curve (AUC-SROC). In addition, the non-Chinese population had pooled AUCs greater than the Chinese population for all indices. Pooled ORs showed that BRI is associated with an increased MetS risk. In conclusion, BRI had good discriminatory power for MetS in adults of both sexes from diverse populations (AUC > 0.7; AUC-SROC > 0.7). However, WC and WHtR offer the best performance when screening for MetS, and non-significant differences were found with BRI. In contrast, BRI was superior to BMI, WHR, ABSI and BAI in predicting MetS.

## KEYWORDS

anthropometric indices, body roundness index, metabolic syndrome, review

## 1 | INTRODUCTION

Metabolic syndrome (MetS) is defined by a clustering of several risk factors for cardiovascular morbidity and mortality,<sup>1–3</sup> including obesity, dyslipidaemia, elevated blood pressure and glucose metabolism disorders. Those are an important risk factors for subsequent development of cardiovascular disease (CVD) and/or type 2 diabetes (T2DM).<sup>4</sup> MetS has become a major health concern in both developing and developed countries affecting a third of adults according the National Health and Nutrition Examination Survey (NHANES).<sup>5</sup>

Obesity, characterized by excess body fat and increased mortality,<sup>6</sup> has been demonstrated to be the main cause of MetS development.<sup>3,7</sup> It is also known that the accumulation of visceral fat, unlike subcutaneous fat, increases the risk of metabolic and cardiovascular disease.<sup>8</sup> Therefore, it is accepted that the body fat distribution, as opposed to the total amount of fat tissue, is a crucial factor of metabolic abnormalities.<sup>9</sup> In this context, the most effective way to assess adiposity is by direct measurement through magnetic resonance imaging or computed tomography.<sup>10</sup> However, the limited accessibility and high cost of these methods hamper their use in daily clinical practice. Consequently, body fat has been habitually determined by a series of anthropometric indices in most studies.

Sergio Rico-Martín and Julián F. Calderón-García contributed equally to this work.

Anthropometric measures are considered as simple, low-cost, non-invasive tools for population screening and early detection.<sup>11</sup> Body mass index (BMI), calculated as weight in kilograms divided by the square of the height in metres ( $\text{kg}/\text{m}^2$ ), is the most commonly used anthropometric index to categorize overweight and obesity in epidemiological and clinical studies.<sup>12–14</sup> BMI has been shown to be a risk factor for various cardiovascular and metabolic disorders and mortality.<sup>15–19</sup> However, it does not discriminate between lean mass and fat mass, and it does not differentiate the location of peripheral/central fat<sup>20,21</sup>; moreover, there is evidence that higher muscle mass reduces risk, whereas greater fat mass is associated with an increased risk of early death.<sup>22</sup> Waist circumference (WC) is a common anthropometric measure for testing central obesity, is a diagnostic constituent of MetS<sup>7,23–25</sup> and is strongly associated to CVD.<sup>26–28</sup> The main limitation of WC is that it does not take into account the subject's weight and height<sup>29</sup> and can underestimate or overestimate obesity in short or tall individuals.<sup>27</sup>

Alternatively, abdominal obesity indices, such as waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR), have been suggested to be better predictors of metabolic and cardiovascular abnormalities because of addressing the limitations of WC and BMI. WHtR, WHR and WC have been reported to better discriminate CVD risks than BMI.<sup>26,27</sup> WC and WHR were reported to have similar associations with hypertension<sup>30,31</sup> and T2DM.<sup>32,33</sup> Furthermore, WHtR has been shown to be statistically more important than BMI and WC in predicting diabetes.<sup>27</sup> Nevertheless, assessing height in addition to WC appeared to have no extra benefit.<sup>34</sup>

Recently, novel anthropometric indices combining traditional measures (height, weight, WC and hip circumference) have been explored.<sup>35–40</sup> Thus, in the last decade, body roundness index (BRI), body shape index (ABSI)<sup>36</sup> and body adiposity index (BAI)<sup>38</sup> have been suggested as an alternative to traditional anthropometric indices. BRI, defined as  $364.2 - 365.5 \times \{1 - [(WC/2\pi)/(0.5 \times \text{height})]^2\}^{0.5}$  was proposed in 2013.<sup>35</sup> BRI is a predictor of body fat percentage and visceral adiposity tissue, and its values range from 1 to 16.<sup>35</sup> Although studies have compared the prediction of MetS by BRI with traditional and novel anthropometric indices,<sup>41–55</sup> there is currently no meta-analysis indicating whether BRI is a better predictor of MetS than BMI, WC, WHR, WHtR, ABSI or BAI. Therefore, this meta-analysis aims to investigate whether BRI is superior to BMI, WC, WHR, WHtR, ABSI or BAI in predicting MetS.

## 2 | METHODS

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.<sup>56</sup>

### 2.1 | Search strategy and study selection

A systematic search was performed in PubMed, Scopus and Web of Science (WOS) databases up until 31 October 2019. We used the

following keywords: 'Body roundness index' or 'BRI' and 'Metabolic Syndrome'. All articles with Spanish or English abstracts and full texts were assessed. We did not utilize a year limit or filters.

Two independent researchers (C.F.A and P.R.S) conducted title and abstract selection and identified potentially eligible articles for the full-text review. Studies that had unclear titles were read entirely. Disagreements were solved by consensus with the third reviewer (J.F.S. M.T). The following inclusion criteria were used:

1. Study design: observational studies observational (including cohort, case-control and cross-sectional studies) published in peer review journals up until 31 October 2019.
2. Participants: individuals aged  $\geq 18$  years
3. Anthropometric measurement: BRI
4. Objective: to assess the predictive value of BRI for MetS
5. For the meta-analysis: studies reporting predictive measures: area under curve (AUC) or odds ratio (OR) with 95% confidence interval (95% CI).

Studies that met any of the following criteria were excluded:

1. Review articles, protocol studies, letters to the editor or conference abstracts
2. Studies of children or adolescents
3. Studies that reported no predictive statistics for BRI for metabolic syndrome
4. Papers without an abstract and full text in English or Spanish.

### 2.2 | Data extraction

Two independent reviewers (J.F.C.G and S.R.M) extracted the following relevant data from each included study: first author identification (year of publication), country, study design, sample size (proportion of males), population characteristics, age range of participants (and/or mean  $\pm$  standard deviation or median [IQ range]), follow-up duration (if a longitudinal study), MetS criteria, adjusted confounders, statistical method and predictive measure (OR, correlation coefficient and/or AUC) of the anthropometric indices (BRI, BMI, WC, WHR, WHtR, ABSI and BAI).

### 2.3 | Risk of bias


Two independent reviewers (S.R.M and M.M.A) assessed the methodological quality of selected articles using the Observational Cohort and Cross-sectional Studies from the Heart, Lung and Blood Institute<sup>57</sup> criteria. This tool contains 14 items. For each item, a score of 1 was allocated if 'yes' was the answer and a score of 0 was allocated if 'no' or other (i.e., 'cannot be assessed', 'not applicable' or 'not available'). For each study, the overall score (ranging from 0 to 14) was estimated by summing scores across all criteria. Disagreements were solved by consensus with the third reviewer (J.F.S.M.T).

## 2.4 | Statistical analysis

For the meta-analysis, studies with AUC (95% CI) or OR (95% CI) were included. Male and female data were analysed separately. We estimated the pooled effect size of BRI, BMI, WC, WHR, WHtR, ABSI and BAI for predicting MetS. Where articles gave values adjusted for covariates, these values were preferred to unadjusted values. The data on AUC and OR for each study were pooled using the mean value and standard error (SE) and were weighted by the inverse variance method. SEs were calculated with this measure ( $SE = \text{upper limit of 95\% CI} - \text{AUC or OR}/1.96$ ). For ORs, the pooled size effect was estimated by how it was reported in the study (i.e., tertiles, quartiles or uncategorized). In addition, a more robust analysis was conducted using studies that published sensitivity and specificity values. We constructed the summary receiver operating characteristic (SROC) curve, which was a measure of the diagnostic accuracy of the anthropometric indices.<sup>58,59</sup> AUC-SROC values were analysed to describe test accuracy. We classified the anthropometric indices in relation to their

discriminatory power by the AUC and AUC-SROC using values proposed by Swets,<sup>60</sup> with  $\leq 0.5$  considered to have no discriminatory power,  $>0.5$  and  $\leq 0.7$  to have low discriminatory power,  $>0.7$  and  $\leq 0.9$  to have good discriminatory power, and 1 to be a perfect test. The heterogeneity of results across studies was evaluated using the  $I^2$  statistic,<sup>61</sup> which was interpreted accordingly: 0% to  $\geq 25$  (modest), 25% to 50% (moderate), 50% to 75% (substantial) and 75% to 100% (considerable). A random-effect model was estimated when  $\geq 50\%$  heterogeneity was present and a fixed-effect model was estimated when  $<50\%$  heterogeneity was present.

The pooled AUC/OR values of different indices predicting MetS were compared by  $I^2$  statistics and  $p$ -values. Subgroup analysis was performed to examine whether the heterogeneity of studies could be explained by involving a Chinese or non-Chinese population. Publication bias was assessed by Egger's test.<sup>62</sup> All analyses were performed using Meta-DiSc version 1.4 (Universidad Complutense, Madrid, Spain) and Review Manager software (RevMan V.5.3.5), and  $p < 0.05$  was considered statistically significant.



**FIGURE 1** Study selection flow chart. AUC, area under curve; BRI, body roundness index; MetS, metabolic syndrome; OR, odds ratio; WOS, World of Science

**TABLE 1** Basic characterizes of the studies included in the review

Ref	Author (year)	Country	Study design	Sample size (% male)	Population characteristics	Age range and/or mean $\pm$ SD or median (IQ range)	Follow-up years	MetS criteria	Adjustment
1	Adejumo EJ (2019) <sup>42</sup>	Nigeria	Cross-sectional	535 (27.3%)	-	$\geq 18$ 47.05 $\pm$ 14.34	-	IDF	-
2	Barazzoni R (2019) <sup>48</sup>	Italy	Prospective cohort	1,965 (46.4%)	-	-48.5 $\pm$ 13.0	5.0	NCEP ATP-III	Age, gender, HOMA, MAP, Tryglicerides, diabetes, hypertension, hyperlipidemia.
3	Gil Llinás (2019) <sup>49</sup>	Spain	Cross-sectional	61,283 (57.2%)	Workers	18–69 39.79 $\pm$ 10.35	-	IDF	-
4	Gómez Marcos MA (2019) <sup>50</sup>	Spain	Cross-sectional	2,478 (61.3%)	Intermediate CVR	35–74 62 (56–67)	-	NCEP ATP-III	Age, gender, smoking Status, alcohol consumption, adherence to the Mediterranean diet, physical activity Status, antihypertensive drugs, Antidiabetic drugs and lipid-lowering drugs
5	Li G (2019) <sup>51</sup>	China	Cross-sectional	1,442 (41.3)	Obeses and overweight adults	$\geq 35$	-	IDF	Age, gender, family income, educational level, smoking, drinking, abdominal circumference, physical activity, SBP, DBP, UA, TG, TC, HDL-C, LDL-C, fasting plasma glucose, fasting plasma insulin.
6	Liu B (2019) <sup>52</sup>	China	Cross-sectional	585 (57.9%)	Diabetics-T2	20–79	-	Chinese Diabetes Society	Age, history of diabetes, and body mass index
7	Liu PJ (2016) <sup>53</sup>	China	Cross-sectional	817 (0.0%)	Postmenopausal women	44–70	-	NCEP ATP-III	Age, total cholesterol, low-density lipoprotein cholesterol, uric acid, high-sensitivity C-reactive protein
8	Ramírez-Vélez R, (2019) <sup>54</sup>	Colombia	Cross-sectional	1,502 (39.7%)	Older adults	70 $\pm$ 7.6	-	IDF	Ethnicity, socio-economic status, smoking status, alcohol intake, physical activity 'proxy', and medical conditions (i.e., presence or absence of osteoporosis, cardiovascular diseases, hypertension, diabetes, cancer, or respiratory disease)
9	Stefanescu A (2019) <sup>55</sup>	Peru	Cross-sectional	1,518 (37.3%)	-	39.3 $\pm$ 15.0	-	NCEP ATP-III	Age, smoking status and alcohol
10	Suliga E (2019) <sup>43</sup>	Poland	Cross-sectional	12,328 (33.2%)	-	37–66	-	IDF harmonized	Age, education, physical activity, alcohol consumption and smoking status

TABLE 1 (Continued)

Ref	Author (year)	Country	Study design	Sample size (% male)	Population characteristics	Age range and/or mean $\pm$ SD or median (IQ range)	Follow-up years	MetS criteria	Adjustment
11	Tian S (2016) <sup>41</sup>	China	Cross-sectional	8,126 (46.5%)	-	18–85	-	IDF harmonized	Age, smoking, alcohol status
12	Wang H (2017) <sup>44</sup>	China	Prospective cohort	379 (52.3%)	-	40–65	4.5	IDF harmonized	-
13	Zhang J (2018) <sup>45</sup>	China	Cross-sectional	59,029 (61.2%)	-	18–80	-	IDF harmonized	Age
14	Zhou C (2019) <sup>46</sup>	China	Cross-sectional	1,603 (59.3%)	Haemodialysis patients	54.6 $\pm$ 16.0	-	IDF	Age, sex, educational status and history of smoking

Abbreviations: CVR: cardiovascular risk; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA, homeostatic model assessment; IDF, International Diabetes Federation; IQ, interquartile; LDL-C, low-density lipoprotein cholesterol; MAP, mean arterial pressure; MetS, metabolic syndrome; NCEP ATP-III, National Cholesterol Education Program Adult Treatment Panel III; SD, standard deviation; SBP, systolic blood pressure; UA, urinalysis; TG, triglycerides; TC, Total cholesterol.

### 3 | RESULTS

#### 3.1 | Selection of studies

Figure 1 shows the article selection process. The literature search identified 58 references through keyword search, including 17 articles from PubMed, 15 from Scopus and 22 from WOS. Of these, 33 were duplicates, resulting in 21 articles. After screening titles and abstracts, three studies were excluded. Eighteen papers were retained for review after full-text evaluation. Of these, four articles were excluded. Therefore, 14 studies met the inclusion criteria and were included in the systematic review, and 13 articles had sufficient data for the meta-analysis.

#### 3.2 | Characteristics of studies

Table 1 shows details about the 14 papers included in the systematic review. Of these, 13 reported cross-sectional studies, and two reported prospective studies.<sup>44,48</sup> The longest follow-up was 5 years.<sup>48</sup> All included papers were published between 2016 and 2019. These studies were conducted in 7 countries including China ( $n = 7$ ), Spain ( $n = 2$ ), Nigeria ( $n = 1$ ), Italy ( $n = 1$ ), Colombia ( $n = 1$ ), Peru ( $n = 1$ ) and Poland ( $n = 1$ ). The number of subjects varied substantially between the studies (range from 379 to 61,283) with a mean of 10,970 and a median of 1,510. Regarding of the characteristics of the population, seven studies assessed the general population, and seven assessed populations with specific characteristics, including workers, intermediate cardiovascular risk, obese and overweight adults, Type 2 diabetes, postmenopausal women, older adults and haemodialysis patients. The age limits for inclusion into each of the individual studies ranged from 18 years to  $\geq 60$  years. Papers used different MetS diagnostic criteria: four studies used National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) criteria; five used International Diabetes Federation (IDF) criteria; four used IDF harmonized criteria, and one used Chinese Diabetes Society criteria. Among the 14 included studies, 10 adjusted for health-related characteristics (e.g., diabetes, smoking status, alcohol intake, physical activity, hypertension and others).

Table 2 summarizes the predictive measures used in the 14 included studies. In 12 papers, the information was stratified by sex. All studies assessed BRI, 13 also assessed BMI; 10 assessed WC; 5 assessed WHR; 11 assessed WHtR; 12 assessed ABSI, and four assessed BAI. Predictive measures included were AUC, OR and multiple regression analysis ( $\beta$  coefficient). The longitudinal study provided baseline and follow-up data.

#### 3.3 | Meta-analysis

A meta-analysis was conducted to assess the performance of BRI in predicting MetS and to assess whether it was a better predictor than BMI, WC, WHR and WHtR.

**TABLE 2** Measures of the studies included in the review

First author (year)	Outcome assessment	BRI	BMI (kg/m <sup>2</sup> )	WC (cm)	WHR	WHtR	ABSI	BAI
Adejumo EJ (2019) <sup>42</sup>	AUC (95%CI)	Men: 0.740 (0.635–0.846) Women: 0.742 (0.689–0.796)	Men: 0.807 (0.717–0.898) Women: 0.768 (0.715–0.821)	Men: 0.814 (0.721–0.907) Women: 0.819 (0.771–0.867)		Men: 0.773 (0.673–0.874) Women: 0.787 (0.737–0.837)	Men: 0.616 (0.491–0.740) Women: 0.554 (0.482–0.625)	Men: 0.722 (0.595–0.850) Women: 0.766 (0.712–0.819)
Barazzoni R (2019) <sup>48</sup>	Coefficient (SE)	Baseline all population $\beta = 0.785$ (0.062); $p < 0.001$ Baseline overweight/obese $\beta = 0.599$ (0.069) $p < 0.001$ Follow-up overweight/obese $\beta = 0.347$ (0.110); $p = 0.002$	Baseline all population $\beta = 0.251$ (0.020); $p < 0.001$ Baseline overweight/obese $\beta = 0.204$ (0.024); $p < 0.001$ Follow-up overweight/obese $\beta = 0.140$ (0.041); $p < 0.001$	Baseline all population $\beta = 0.079$ (0.007); $p < 0.001$ Baseline overweight/obese $\beta = 0.064$ (0.004); $p < 0.001$ Follow-up overweight/obese $\beta = 0.048$ (0.016); $p = 0.002$		Baseline all population $\beta = 18.881$ (1.444); $p < 0.001$ Baseline overweight/obese $\beta = 15.129$ (1.650); $p < 0.001$ Follow-up overweight/obese $\beta = 8.933$ (2.672); $p = 0.001$	Baseline all population $\beta = 6.459$ (1.411); $p < 0.001$ Baseline overweight/obese $\beta = 8.803$ (1.905); $p < 0.001$ Follow-up overweight/obese $\beta = 0.917$ (3.091); $p = 0.767$	
Gil Llinás M (2019) <sup>49</sup>	AUC (95%CI)	IDF definition Men: 0.937 (0.935–0.940) Women: 0.924 (0.919–0.928) NECPT ATP III definition Men: 0.871 (0.863–0.878) Women: 0.873 (0.862–0.885)	IDF definition Men: 0.830 (0.824–0.836) Women: 0.857 (0.849–0.866) NECPT ATP-III definition Men: 0.793 (0.785–0.800) Women: 0.839 (0.828–0.850)	IDF definition Men: 0.813 (0.806–0.820) Women: 0.769 (0.756–0.781) NECPT ATP-III definition Men: 0.775 (0.765–0.784) Women: 0.756 (0.739–0.772)	IDF definition Men: 0.937 (0.935–0.940) Women: 0.924 (0.919–0.928) NECPT ATP-III definition Men: 0.871 (0.863–0.878) Women: 0.874 (0.862–0.885)	IDF definition Men: 0.706 (0.697–0.715) Women: 0.595 (0.578–0.612) NECPT ATP-III definition Men: 0.676 (0.665–0.686) Women: 0.610 (0.590–0.630)	IDF definition Men: 0.734 (0.727–0.742) Women: 0.762 (0.750–0.774) NECPT ATP-III definition Men: 0.716 (0.708–0.725) Women: 0.756 (0.741–0.771)	
Gómez Marcos MA (2019) <sup>50</sup>	OR (95% CI)	Men: 5.96 (4.66–7.63) Women: 4.15 (3.09–5.58)	Men: 5.98 (4.70–7.60) Women: 4.14 (3.07–5.58)	Men: 5.93 (4.63–7.58) Women: 4.15 (3.09–5.58)	Men: 1.65 (1.31–2.07) Women: 1.81 (1.37–2.39)	Men: 0.567 (0.538–0.596) Women: 0.569 (0.554–0.626)		
Li G (2019) <sup>51</sup>	AUC (95%CI)	Men: 0.761 (0.738–0.785) Women: 0.735 (0.704–0.767)	Men: 0.773 (0.749–0.796) Women: 0.718 (0.686–0.750)	Men: 0.761 (0.738–0.785) Women: 0.735 (0.704–0.767)	Men: 0.567 (0.538–0.596) Women: 0.569 (0.554–0.626)			
	OR (95% CI)	Men: Q1: Ref Q4: 1.986 (1.175–3.356) Women: Q1: Ref Q4: 1.679 (1.283–2.197)	Men: Q1: Ref Q4: 1.239 (0.674–2.276) Women: Q1: Ref Q4: 1.008 (0.654–1.556)	Men: Q1: Ref Q4: 3.276 (1.706–6.293) Women: Q1: Ref Q4: 2.908 (2.000–4.228)	Men: Q1: Ref Q4: 0.797 (0.403–1.577) Women: Q1: Ref Q4: 0.604 (0.381–0.957)	Men: Q1: Ref Q4: 1.686 (0.958–2.381) Women: Q1: Ref Q4: 2.206 (0.976–2.897)		
	AUC (95%CI)	Men: 0.745 (0.704–0.785) Women: 0.727 (0.693–0.761)	Men: 0.725 (0.684–0.767) Women: 0.678 (0.642–0.714)	Men: 0.764 (0.724–0.804) Women: 0.738 (0.704–0.772)	Men: 0.652 (0.607–0.697) Women: 0.637 (0.599–0.674)	Men: 0.636 (0.590–0.683) Women: 0.609 (0.559–0.658)		



TABLE 2 (Continued)


First author (year)	Outcome assessment	BRI	BMI (kg/m <sup>2</sup> )	WC (cm)	WHR	WHtR	ABSI	BAI
Liu B (2019) <sup>52</sup>	OR (95% CI)	Men: T1: Ref T2: 5.035 (2.560–9.904) T3: 7.195 (2.576–20.099) Women: T1: Ref T2: 4.616 (2.056–10.363) T3: 3.772 (1.345–10.577)						
		Men: 0.824 (0.775–0.874) Women: 0.775 (0.702–0.848)	Men: 0.842 (0.794–0.891) Women: 0.798 (0.726–0.870)			Men: 0.825 (0.776–0.875) Women: 0.775 (0.702–0.848)		
			Women: 0.842 (0.794–0.891) Women: 0.798 (0.726–0.870)	Women: WHtR <0.5; Ref WHtR ≥0.5: 2.347 (1.713–3.215)		Women: T1: Ref T2: 1.003 (0.699–1.439) T3: 1.240 (0.840–1.833)		
			Women: WHtR <0.5; Ref WHtR ≥0.5: 2.347 (1.713–3.215)		Women: 0.567 (0.527–0.607)			
Liu PJ (2016) <sup>53</sup>	OR (95% CI)	Women: T1: Ref T2: 2.068 (1.414–3.022) T3: 2.812 (1.882–4.200)	Women: BMI < 24.0; Ref BMI 24.0–27.9: 2.474 (1.780–3.437) BMI ≥ 28.0: 3.348 (2.000–5.602)	Women: 0.691 (0.655–0.727)	Women: 0.670 (0.633–0.707)			
		Women: 0.683 (0.647–0.720)	Women: 0.683 (0.647–0.719)					
			Men: 0.77 Women: 0.77	Men: 0.76 Women: 0.71	Men: 0.77 Women: 0.77	Men: 0.60 Women: 0.62		
			Men: 2.43 (1.95–3.02) Women: 1.89 (1.68–2.12)	Men: 1.38 (1.28–1.48) Women: 1.21 (1.17–1.26)	Men: 1.15 (1.12–1.19) Women: 1.11 (1.09–1.13)	Men: 0.99 (0.95–1.04) Women: 1.07 (1.04–1.10)		
Stefanescu A (2019) <sup>55</sup>	AUC (95%CI)	Men: 0.81 (0.77–0.85) Women: 0.83 (0.80–0.85)	Men: 0.81 (0.77–0.86) Women: 0.78 (0.75–0.81)	Men: 0.85 (0.81–0.89) Women: 0.83 (0.81–0.86)				
			Men: 0.81 (0.77–0.85) Women: 0.83 (0.80–0.85)	Men: 0.81 (0.77–0.86) Women: 0.78 (0.75–0.81)	Men: 0.85 (0.81–0.89) Women: 0.83 (0.81–0.86)	Men: 0.57 (0.51–0.63) Women: 0.65 (0.61–0.69)		
			Men: 0.81 (0.77–0.85) Women: 0.83 (0.80–0.85)	Men: 0.81 (0.77–0.86) Women: 0.78 (0.75–0.81)	Men: 0.85 (0.81–0.89) Women: 0.83 (0.81–0.86)	Men: 0.57 (0.51–0.63) Women: 0.65 (0.61–0.69)		
			Men: 0.81 (0.77–0.85) Women: 0.83 (0.80–0.85)	Men: 0.81 (0.77–0.86) Women: 0.78 (0.75–0.81)	Men: 0.85 (0.81–0.89) Women: 0.83 (0.81–0.86)	Men: 0.57 (0.51–0.63) Women: 0.65 (0.61–0.69)		
Suliga E (2019) <sup>43</sup>	OR (95%CI)	Men: Q1: Ref Q5: 11.81 (9.25–15.09) Women: Q1: Ref Q5: 16.44 (13.32–20.29)	Men: Q1: Ref Q5: 17.52 (13.57–22.62) Women: Q1: Ref Q5: 12.76 (10.53–15.46)	Men: Q1: Ref Q5: 24.87 (18.85–32.82) Women: Q1: Ref Q5: 25.61 (20.26–202.4)	Men: Q1: Ref Q5: 24.87 (18.85–32.82) Women: Q1: Ref Q5: 25.61 (20.26–202.4)	Men: Q1: Ref Q5: 2.46 (1.99–3.04) Women: Q1: Ref Q5: 3.45 (2.94–4.05)		
			Men: 0.728 (0.713–0.743) Women: 0.748 (0.737–0.758)	Men: 0.754 (0.739–0.769) Women: 0.731 (0.720–0.742)	Men: 0.764 (0.749–0.778) Women: 0.758 (0.748–0.768)	Men: 0.603 (0.586–0.620) Women: 0.639 (0.627–0.651)		
			Men: 0.728 (0.713–0.743) Women: 0.748 (0.737–0.758)	Men: 0.754 (0.739–0.769) Women: 0.731 (0.720–0.742)	Men: 0.764 (0.749–0.778) Women: 0.758 (0.748–0.768)	Men: 0.603 (0.586–0.620) Women: 0.639 (0.627–0.651)		
			Men: 0.728 (0.713–0.743) Women: 0.748 (0.737–0.758)	Men: 0.754 (0.739–0.769) Women: 0.731 (0.720–0.742)	Men: 0.764 (0.749–0.778) Women: 0.758 (0.748–0.768)	Men: 0.603 (0.586–0.620) Women: 0.639 (0.627–0.651)		



TABLE 2 (Continued)

First author (year)	Outcome assessment	BRI	BMI (kg/m <sup>2</sup> )	WC (cm)	WHR	WHR	WHR	ABSI	BAI
Tian S (2016) <sup>41</sup>	OR (95% CI)	Men: Q1: Ref Q4: 7.53 (6.03–9.39) Women: Q1: Ref Q4: 4.74 (3.82–5.88)	Men: Q1: Ref Q4: 9.22 (7.35–11.56) Women: Q1: Ref Q4: 5.7 (4.64–7.01)	Men: Q1: Ref Q4: 8.06 (6.46–10.05) Women: Q1: Ref Q4: 4.79 (3.88–5.91)	Men: Q1: Ref Q4: 5.11 (4.15–6.3) Women: Q1: Ref Q4: 3.4 (2.77–4.19)	Men: Q1: Ref Q4: 4.74 (3.82–5.88) Men: 0.71 (0.693–0.727) Women: 0.703 (0.687–0.719)	Men: Q1: Ref Q4: 1.63 (1.33–1.99) Women: Q1: Ref Q4: 1.30 (1.06–1.60)	Men: Q1: Ref Q4: 1.63 (1.33–1.99) Women: Q1: Ref Q4: 1.30 (1.06–1.60)	Men: Q1: Ref Q4: 1.63 (1.33–1.99) Women: Q1: Ref Q4: 1.30 (1.06–1.60)
		Men: 0.710 (0.693–0.727) Women: 0.703 (0.687–0.719)	Men: 0.717 (0.7–0.734) Women: 0.692 (0.675–0.708)	Men: 0.672 (0.654–0.689) Women: 0.699 (0.683–0.715)	Men: 0.672 (0.654–0.689) Women: 0.657 (0.641–0.674)	Men: 0.71 (0.693–0.727) Women: 0.703 (0.687–0.719)	Men: 0.572 (0.553–0.591) Women: 0.586 (0.569–0.604)	Men: 0.572 (0.553–0.591) Women: 0.586 (0.569–0.604)	Men: 0.572 (0.553–0.591) Women: 0.586 (0.569–0.604)
		AUC (95% CI)							
		Baseline: Men: 0.76 (0.69–0.83) Women: 0.80 (0.71–0.88) Follow-up: Men: 0.74 (0.65–0.82) Women: 0.71 (0.63–0.79)	Baseline: Men: 0.73 (0.65–0.80) Women: 0.75 (0.67–0.84) Follow-up: Men: 0.77 (0.68–0.85) Women: 0.71 (0.63–0.78)	Baseline: Men: 0.79 (0.72–0.86) Women: 0.79 (0.71–0.87) Follow-up: Men: 0.76 (0.67–0.84) Women: 0.71 (0.64–0.79)	Baseline: Men: 0.72 (0.64–0.79) Women: 0.75 (0.67–0.83) Follow-up: Men: 0.73 (0.64–0.81) Women: 0.68 (0.59–0.75)	Baseline: Men: 0.70 (0.62–0.78) Women: 0.62 (0.52–0.72) Follow-up: Men: 0.58 (0.49–0.68) Women: 0.55 (0.47–0.64)	Baseline: Men: 0.67 (0.59–0.75) Women: 0.69 (0.59–0.79) Follow-up: Men: 0.59 (0.49–0.68) Women: 0.64 (0.56–0.72)	Baseline: Men: 0.67 (0.59–0.75) Women: 0.69 (0.59–0.79) Follow-up: Men: 0.59 (0.49–0.68) Women: 0.64 (0.56–0.72)	Baseline: Men: 0.67 (0.59–0.75) Women: 0.69 (0.59–0.79) Follow-up: Men: 0.59 (0.49–0.68) Women: 0.64 (0.56–0.72)
Zhang J (2018) <sup>45</sup>	OR (95% CI)	Men: 2.410 (2.346–2.477) Women: 2.250 (2.160–2.344)	Men: 2.423 (2.359–2.489) Women: 2.241 (2.157–2.329)	Men: 2.399 (2.335–2.464) Women: 2.254 (2.165–2.347)	Men: 2.455 (2.389–2.523) Women: 2.348 (2.251–2.448)	Men: 2.455 (2.389–2.523) Women: 2.348 (2.251–2.448)	Men: 1.238 (1.120–1.267) Women: 1.224 (1.180–1.269)	Men: 1.238 (1.120–1.267) Women: 1.224 (1.180–1.269)	Men: 1.238 (1.120–1.267) Women: 1.224 (1.180–1.269)
		Men: 0.727 (0.721–0.732) Women: 0.782 (0.776–0.789)	Men: 0.719 (0.714–0.724) Women: 0.760 (0.753–0.767)	Men: 0.721 (0.716–0.726) Women: 0.770 (0.763–0.777)	Men: 0.727 (0.721–0.732) Women: 0.782 (0.776–0.789)	Men: 0.727 (0.721–0.732) Women: 0.782 (0.776–0.789)	Men: 0.585 (0.579–0.591) Women: 0.648 (0.640–0.657)	Men: 0.585 (0.579–0.591) Women: 0.648 (0.640–0.657)	Men: 0.585 (0.579–0.591) Women: 0.648 (0.640–0.657)
		AUC (95% CI)							
		Baseline: Men: 0.76 (0.69–0.83) Women: 0.80 (0.71–0.88) Follow-up: Men: 0.74 (0.65–0.82) Women: 0.71 (0.63–0.79)	Baseline: Men: 0.73 (0.65–0.80) Women: 0.75 (0.67–0.84) Follow-up: Men: 0.77 (0.68–0.85) Women: 0.71 (0.63–0.78)	Baseline: Men: 0.79 (0.72–0.86) Women: 0.79 (0.71–0.87) Follow-up: Men: 0.76 (0.67–0.84) Women: 0.71 (0.64–0.79)	Baseline: Men: 0.72 (0.64–0.79) Women: 0.75 (0.67–0.83) Follow-up: Men: 0.73 (0.64–0.81) Women: 0.68 (0.59–0.75)	Baseline: Men: 0.70 (0.62–0.78) Women: 0.62 (0.52–0.72) Follow-up: Men: 0.58 (0.49–0.68) Women: 0.55 (0.47–0.64)	Baseline: Men: 0.67 (0.59–0.75) Women: 0.69 (0.59–0.79) Follow-up: Men: 0.59 (0.49–0.68) Women: 0.64 (0.56–0.72)	Baseline: Men: 0.67 (0.59–0.75) Women: 0.69 (0.59–0.79) Follow-up: Men: 0.59 (0.49–0.68) Women: 0.64 (0.56–0.72)	Baseline: Men: 0.67 (0.59–0.75) Women: 0.69 (0.59–0.79) Follow-up: Men: 0.59 (0.49–0.68) Women: 0.64 (0.56–0.72)
Zhou C (2019) <sup>46</sup>	OR (95% CI)	Men: 26.33 (16.42–42.22)	Men: 12.35 (8.17–18.65) Q4: 28.27 (17.62–45.35)	Men: 28.27 (17.62–45.35)	Men: 23.23 (12.89–41.86)	Men: 23.23 (12.89–41.86)	Q1: Ref Q4: 2.89 (2.02–4.15)	Q1: Ref Q4: 2.89 (2.02–4.15)	Q1: Ref Q4: 2.89 (2.02–4.15)
		Men: 0.78 (0.74–0.81) Women: 0.79 (0.75–0.82)	Men: 0.76 (0.73–0.79) Women: 0.81 (0.77–0.84)	Men: 0.79 (0.76–0.82) Women: 0.81 (0.77–0.84)	Men: 0.78 (0.74–0.81) Women: 0.79 (0.75–0.83)	Men: 0.78 (0.74–0.81) Women: 0.79 (0.75–0.83)	Men: 0.60 (0.57–0.64) Women: 0.65 (0.61–0.69)	Men: 0.60 (0.57–0.64) Women: 0.65 (0.61–0.69)	Men: 0.60 (0.57–0.64) Women: 0.65 (0.61–0.69)
		AUC (95% CI)							
		Baseline: Men: 0.76 (0.69–0.83) Women: 0.80 (0.71–0.88) Follow-up: Men: 0.74 (0.65–0.82) Women: 0.71 (0.63–0.79)	Baseline: Men: 0.73 (0.65–0.80) Women: 0.75 (0.67–0.84) Follow-up: Men: 0.77 (0.68–0.85) Women: 0.71 (0.63–0.78)	Baseline: Men: 0.79 (0.72–0.86) Women: 0.79 (0.71–0.87) Follow-up: Men: 0.76 (0.67–0.84) Women: 0.71 (0.64–0.79)	Baseline: Men: 0.72 (0.64–0.79) Women: 0.75 (0.67–0.83) Follow-up: Men: 0.73 (0.64–0.81) Women: 0.68 (0.59–0.75)	Baseline: Men: 0.70 (0.62–0.78) Women: 0.62 (0.52–0.72) Follow-up: Men: 0.58 (0.49–0.68) Women: 0.55 (0.47–0.64)	Baseline: Men: 0.67 (0.59–0.75) Women: 0.69 (0.59–0.79) Follow-up: Men: 0.59 (0.49–0.68) Women: 0.64 (0.56–0.72)	Baseline: Men: 0.67 (0.59–0.75) Women: 0.69 (0.59–0.79) Follow-up: Men: 0.59 (0.49–0.68) Women: 0.64 (0.56–0.72)	Baseline: Men: 0.67 (0.59–0.75) Women: 0.69 (0.59–0.79) Follow-up: Men: 0.59 (0.49–0.68) Women: 0.64 (0.56–0.72)

Abbreviations: AUC, area under curve; BMI, body mass index; BRI, body roundness index; CI, confidence interval; IDF, International Diabetes Federation; NECP ATP-III, National Cholesterol Educational Program Adult Treatment Panel III; Q, quartile; T, tertile; OR, odds ratio; WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio.



**FIGURE 2** Estimated pooled AUC for BRI (A), BMI (B), WC (C), WHR (D), WHtR (E), ABSI (F) and BAI (G). ABSI, body shape index; AUC, area under curve; BAI, body adiposity index; BMI, body mass index; BRI, body roundness index; CI, confidence interval; WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio

Figure 2A–G shows the forest plots of the pooled AUC values and lower and upper 95% CIs of BRI, BMI, WC, WHR, WHtR, ABSI and BAI for MetS for both sexes. For all indices, pooled AUC values were greater than 0.70 (good discriminatory power), except for ABSI

(AUC = 0.61 for men, women and all subjects), WHR and BAI in women (AUC = 0.69 and AUC = 0.68, respectively). The pooled AUCs for BRI were 0.76 (0.72–0.80) in women, 0.77 (0.71–0.84) in men and 0.77 (0.73–0.80) for all subjects. WHtR had pooled AUCs greater than




FIGURE 2 (Continued)

0.77 (0.73–0.82) in women, 0.78 (0.69–0.88) in men and 0.78 (0.72–0.83) in all subjects. The estimated pooled AUC for BRI predicting MetS was 0.07 (95% CI [0.01–0.13];  $I^2 = 82.0\%$ ;  $p = 0.02$ ), which was higher than that of WHR and BAI for all subjects, but not for men or women separately. Moreover, pooled AUCs for BRI were significantly greater than AUCs for ABSI, 0.16 (95% CI [0.12–0.2];  $I^2 = 98.0\%$ ;  $p < 0.001$ ) in both women and men. The difference between BRI and BMI, WC and WHtR in predicting MetS was not statistically significant.

The pooled AUC values for anthropometric indices for Chinese populations and non-Chinese populations were examined to explore differences across populations (Table 3). Non-Chinese populations had a pooled AUC greater than the Chinese populations for all indices. Using BRI for women in non-Chinese populations, the estimated

pooled AUC was 0.05 (95% CI [0.01–0.10];  $I^2 = 73.0\%$ ;  $p = 0.04$ ), which was higher than for women in the Chinese population, but there were no significant differences between subgroups for men or for all subjects. Pooled AUCs of WC and BAI were significantly different in both men and women. Pooled AUCs for WHR were significantly different in the entire population, but only one study was included in the non-Chinese population, and pooled BMI was significantly different in men and the entire population. There were no significant differences between subgroups for WHtR and ABSI. When we compared pooled AUCs for BRI with the other anthropometric indices in the Chinese population, we observed that pooled AUCs for BRI were significantly greater than AUCs for WHR in men, 0.07 (95% CI [0.03–0.11];  $I^2 = 90.0\%$ ;  $p < 0.001$ ), women, 0.08 (95% CI [0.04–0.12];  $I^2 = 95.0\%$ ;  $p < 0.001$ ), and all subjects, 0.08 (95% CI





FIGURE 2 (Continued)

[0.05–0.11];  $I^2 = 97.0\%$ ;  $p < 0.001$ ). Further, pooled AUCs for BRI were significantly higher than AUCs for ABSI in men, 0.13 (95% CI [0.10–0.16];  $I^2 = 99.0\%$ ;  $p < 0.001$ ), women, 0.12 (95% CI [0.07–0.17];  $I^2 = 98.0\%$ ;  $p < 0.001$ ) and all subjects 0.13 (95% CI [0.09–0.17];  $I^2 = 99.0\%$ ;  $p < 0.001$ ). Between BRI and BMI in all subjects, the difference in AUC was 0.03 (95% CI [0.01, 0.05];  $I^2 = 86.0\%$ ;  $p = 0.009$ ). However, in the non-Chinese population, there were no significant differences between BRI and the other anthropometric indices analysed, except for ABSI, where pooled AUCs for BRI were significantly greater in men, 0.18 (95% CI [0.07–0.29];  $I^2 = 89.0\%$ ;  $p = 0.003$ ), women, 0.19 (95% CI [0.15–0.23];  $I^2 = 98.0\%$ ;

$p < 0.001$ ), and all subjects, 0.18 (95% CI [0.11–0.25];  $I^2 = 96.0\%$ ;  $p < 0.001$ ).

Among the 13 included studies, seven reported values for sensitivity and specificity (Table 4). We constructed the SROC to estimate the pooled AUC-SROC (Figure 3–5). For both sexes, the SROC was not calculated for WHR because only two studies reported data necessary for estimation. The pooled AUC-SROC (95% CI) for BRI was 0.77 (0.73–0.83) for females, 0.79 (0.74–0.87) for males, and 0.80 (0.76–0.84) for all subjects. These values were greater than pooled AUCs estimated by the inverse variance method. The pooled AUC-SROC for BRI was significantly greater than the AUC-SROC for ABSI





**FIGURE 2** (Continued)

in men, 0.17 (95% CI [0.11–0.23];  $I^2 = 96.0\%$ ;  $p < 0.001$ ), women, 0.15 (95% CI [0.10–0.20];  $I^2 = 97.0\%$ ;  $p < 0.001$ ) and all subjects, 0.16 (95% CI [0.12–0.20];  $I^2 = 100.0\%$ ;  $p < 0.001$ ). Further, pooled AUC-SROCs for BRI were non-significantly higher than AUC-SROCs for BMI and BAI but lower for WC and WHtR. In the entire population, an SROC was possible (Figure 5D). The pooled AUC-SROC for WHR was lower than the AUC-SROC for BRI, but significant differences were not found.

Table 5 shows pooled odds ratios. For both sexes and types of population, increased BRI was associated with increased odds of MetS. Pooled ORs in tertiles were only obtained for BRI in women. Pooled ORs could not be summarized for BAI. In the non-Chinese population, uncategorized pooled ORs could not be calculated for WC, WHR or WHtR in men, women or all subjects. In addition, for WHR, they could not be obtained for either population (Chinese or non-Chinese population). For WHtR, pooled OR quartiles could not be calculated. In women, men and all subjects, pooled ORs for BRI were greater than BMI (quartiles and uncategorized), WC (quartiles) WHR (quartiles) and ABSI (quartiles and uncategorized) but were lower than WC and WHtR (Chinese and non-Chinese population, uncategorized pooled ORs). However, significant differences were not found between BRI and the other anthropometric indices analysed, except for ABSI, where pooled ORs for BRI were significantly greater in women (Chinese and non-Chinese population, uncategorized pooled ORs), men (uncategorized) and all the subjects (quartiles and uncategorized).

### 3.4 | Quality of studies and publication bias

The results of the quality assessment using the Observational Cohort and Cross-sectional Studies from the Heart, Lung and Blood Institute are shown in Table S1. The included studies on average scored 9.21 out of 14, with a range from 8 to 14. Only one study scored a 14. Because of the characteristics of the included studies (86% were

cross-sectional studies), the most frequent limitations were the lack of sample size justification and repeated evaluation of anthropometric indices during the study period. Evidence of publication bias was not found by Egger's test ( $p > 0.1$ ).

## 4 | DISCUSSION

This meta-analysis, including data on more than 150,000 individuals, showed that BRI had good discriminatory power for MetS in adults of both sexes from diverse populations (71,981 Chinese). The estimated pooled AUCs for BRI predicting MetS were higher than for BMI, WHR, ABSI and BAI, similar to WC and lower than WHtR. However, the differences between BRI and BMI, WC and WHtR in predicting MetS were not statistically significant. In addition, the non-Chinese population had pooled AUCs greater than the Chinese population for all indices. The pooled AUC-SROCs were greater than pooled AUCs, but no significant differences were found with the rest of the anthropometric indices, except for ABSI. Finally, pooled ORs showed that increased BRI was associated with increased MetS risk.

BRI was developed to predict both body fat and the percentage of visceral adipose tissue using WC in relation to height, which allows estimation of the shape of the human body figure as an ellipse or oval.<sup>35</sup> However, BRI is limited in predicting percentage of fat mass in elite athletes when compared with other commonly and readily available field methods such as bio-impedance analysis or skinfold prediction models.<sup>63</sup> Several recent studies have shown that BRI could be used as an adipose indicator for determining the presence of eccentric left ventricular hypertrophy,<sup>64</sup> hyperuricaemia,<sup>41,65</sup> arterial stiffness,<sup>66–69</sup> CVD,<sup>70,71</sup> diabetes,<sup>41,72–75</sup> dyslipidaemia,<sup>41,76–78</sup> hypertension<sup>41,79,80</sup> and MetS.<sup>41–55</sup>

This study is the first study to systematically review scientific evidence regarding the performance of BRI predicting MetS. Up to now, only one meta-analysis had used anthropometric measurements to predict MetS in adults.<sup>27</sup> Researchers assessed the discriminatory

**TABLE 3** Pooled area under the curve categorized by Chinese population or non-Chinese population

	BRI			BMI			WC			WHR			WHtR		
	N	AUC (95%CI)	I <sup>2</sup>	N	AUC (95%CI)	I <sup>2</sup>	N	AUC (95%CI)	I <sup>2</sup>	N	AUC (95%CI)	I <sup>2</sup>	N	AUC (95%CI)	I <sup>2</sup>
Chinese population (n = 71,981)	Women	8	0.74 (0.71–0.78)	93%	8	0.72 (0.68–0.75)	92%	8	0.75 (0.71–0.78)	91%	5	0.66 (0.64–0.69) †††	5	0.75 (0.70–0.80)	96%
	Men	7	0.75 (0.72–0.78)	80%	7	0.73 (0.71–0.75)	41%	7	0.76 (0.72–0.80)	93%	4	0.68 (0.65–0.70)†††	4	0.75 (0.72–0.78)	89%
	Total	15	0.75 (0.73–0.77)	93%	13	0.72 (0.71–0.73)††	91%	15	0.75 (0.73–0.77)	94%	9	0.67 (0.65–0.68)†††	9	0.75 (0.72–0.78)	97%
Non-Chinese population (n = 78,142)	Women	5	0.79 (0.75–0.83)*	99%	5	0.77 (0.70–0.84)	99%	2	0.83 (0.81–0.85)***	0%	1	-	4	0.80 (0.70–0.91)	99%
	Men	5	0.79 (0.69–0.91)	99%	5	0.79 (0.75–0.84)**	94%	2	0.85 (0.81–0.88)***	0%	1	-	4	0.81 (0.70–0.93)	99%
	Total	10	0.79 (0.73–0.85)	99%	10	0.78 (0.75–0.82)***	98%	4	0.83 (0.82–0.85)***	0%	2	0.79 (0.75–0.84)***	8	0.80 (0.74–0.88)	100%
	ABSI			BAI											
	N	AUC (95%CI)	I <sup>2</sup>	N	AUC (95%CI)	I <sup>2</sup>									
Chinese population (n = 71,981)	Women	6	0.62 (0.58–0.65)†††	88%	3	0.62 (0.55–0.70)†††									
	Men	6	0.60 (0.58–0.62)†††	68%	2	0.67 (0.61–0.73)†									
	Total	12	0.61 (0.59–0.64)†††	94%	5	0.64 (0.59–0.70)†††									
Non-Chinese population (n = 78,142)	Women	5	0.60 (0.57–0.64)†††	93%	2	0.76 (0.75–0.77)***									
	Men	5	0.61 (0.55–0.69)†††	97%	2	0.73 (0.72–0.74)*									
	Total	10	0.61 (0.57–0.67)†††	97%	4	0.75 (0.73–0.77)***									

Abbreviations: ABSI, body shape index; AUC, area under curve; BMI, body mass index; BRI, body roundness index; CI, confidence interval; IDF, International Diabetes Federation; WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio.

Differences between Chinese population and non-Chinese population:

\*p < 0.05,  
\*\*p < 0.01,  
\*\*\*p < 0.001.  
†p < 0.05,  
††p < 0.01,  
†††p < 0.001

Differences between BRI and BMI, WC, WHR or WHtR:

TABLE 4 Baseline sensitivity and specificity data of included studies


	Study	Women						Men							
		Cut-off	Sen	Spe	TP	TN	FN	FP	Cut-off	Sen	Spe	TP	TN	FN	FP
BRI	Adejumo EJ 2019 <sup>42</sup>	12.56	0.705	0.664	71	192	30	97	11.90	0.440	0.934	54	21	69	2
	Gil Llinás M 2019 <sup>49</sup>	3.25	0.946	0.784	1,456	19,366	83	5,336	4.30	0.907	0.838	3,721	25,927	382	5,012
	Gómez Marcos MA 2019 <sup>50</sup>	5.77	0.702	0.666	332	323	141	162	5.67	0.675	0.717	437	626	210	247
	Ramírez Vélez R 2019 <sup>54</sup>	6.20	0.652	0.761	166	496	88	156	4.71	0.836	0.589	118	268	23	187
	Whang H 2017 <sup>44</sup>	3.58	0.710	0.660	52	71	21	37	3.47	0.810	0.580	104	40	25	29
	Zhang J 2018 <sup>45</sup>	3.18	0.735	0.689	2,686	13,282	968	5,995	3.55	0.748	0.584	9,776	13,449	3,293	9,580
BMI	Zhou C 2019 <sup>46</sup>	3.91	0.690	0.780	260	215	117	61	3.84	0.660	0.790	249	453	128	121
	Adejumo EJ 2019 <sup>42</sup>	28.30	0.705	0.688	71	199	30	90	27.20	0.640	0.909	79	21	44	2
	Gil Llinás M 2019 <sup>49</sup>	26.00	0.855	0.698	1,316	17,242	223	7,460	27.30	0.847	0.659	3475	20,389	628	10,550
	Gómez Marcos MA 2019 <sup>50</sup>	28.02	0.740	0.606	350	294	123	191	28.96	0.702	0.714	454	623	193	250
	Ramírez Vélez R 2019 <sup>54</sup>	28.40	0.695	0.641	177	418	77	234	25.20	0.844	0.547	119	249	22	206
	Whang H 2017 <sup>44</sup>	25.14	0.590	0.780	43	84	30	24	24.94	0.690	0.750	89	52	40	17
WC	Zhang J 2018 <sup>45</sup>	23.03	0.704	0.688	2,572	13,263	1,082	6,014	24.64	0.709	0.613	9266	14,117	3,803	8,912
	Zhou C 2019 <sup>46</sup>	21.85	0.670	0.760	253	209	124	66	21.97	0.740	0.680	279	390	98	184
	Adejumo EJ 2019 <sup>42</sup>	91.75	0.875	0.635	88	184	13	105	89.50	0.880	0.711	108	16	15	7
	Gil Llinás M 2019 <sup>49</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Gómez Marcos MA 2019 <sup>50</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Ramírez Vélez R 2019 <sup>54</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
WHR	Whang H 2017 <sup>44</sup>	80.00	0.820	0.600	60	65	13	43	84.00	0.950	0.540	123	37	6	32
	Zhang J 2018 <sup>45</sup>	77.25	0.726	0.677	2653	13,051	1001	6226	87.25	0.703	0.621	9,188	14,301	3,881	8,728
	Zhou C 2019 <sup>46</sup>	79.90	0.790	0.780	298	215	79	61	89.95	0.560	0.890	211	511	166	63
	Adejumo EJ 2019 <sup>42</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Gil Llinás M 2019 <sup>49</sup>	0.78	0.771	0.600	1,187	14,821	352	9,881	0.90	0.840	0.619	3447	19151	656	11788
	Gómez Marcos MA 2019 <sup>50</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
WHR	Ramírez Vélez R 2019 <sup>54</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Whang H 2017 <sup>44</sup>	0.81	0.910	0.370	66	40	7	68	0.89	0.760	0.640	98	44	31	25
	Zhang J 2018 <sup>45</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Zhou C 2019 <sup>46</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-



TABLE 4 (Continued)

	Study	Women						Men							
		Cut-off	Sen	Spe	TP	TN	FN	FP	Cut-off	Sen	Spe	TP	TN	FN	FP
WHtR	Adejumo EJ 2019 <sup>42</sup>	0.59	0.761	0.684	76	198	24	91	0.54	0.640	0.777	79	18	44	5
	Gil Llinás M 2019 <sup>49</sup>	0.50	0.906	0.819	1,394	20,231	145	4471	0.53	0.962	0.750	3947	23204	156	7735
	Gómez Marcos MA 2019 <sup>50</sup>	0.61	0.702	0.666	332	323	141	162	0.61	0.675	0.717	437	626	210	247
	Ramírez Vélez R 2019 <sup>54</sup>	0.63	0.644	0.767	164	500	90	152	0.56	0.836	0.586	118	267	23	188
	Whang H 2017 <sup>44</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Zhang J 2018 <sup>45</sup>	0.49	0.735	0.689	2,686	13,282	968	5,995	0.51	0.748	0.584	9776	13,449	3,293	9,580
	Zhou C 2019 <sup>46</sup>	0.53	0.690	0.880	260	242	117	33	0.52	0.660	0.890	249	511	128	63
	ABSI														
	Adejumo EJ 2019 <sup>42</sup>	12.900	0.523	0.611	52	177	48	112	14.150	0.520	0.736	64	17	59	6
	Gil Llinás M 2019 <sup>49</sup>	0.069	0.644	0.462	991	11,412	548	13,290	0.078	0.685	0.629	2,811	19,461	1,292	11,478
	Gómez Marcos MA 2019 <sup>50</sup>	0.080	0.622	0.638	294	309	179	176	0.080	0.592	0.501	383	437	264	436
	Ramírez Vélez R 2019 <sup>54</sup>	0.080	0.687	0.516	174	336	80	316	0.083	0.695	0.536	98	244	43	211
	Whang H 2017 <sup>44</sup>	0.080	0.320	0.810	23	87	50	21	0.082	0.290	0.880	37	61	92	8
	Zhang J 2018 <sup>45</sup>	0.077	0.565	0.655	2065	12,626	1,589	6,651	0.079	0.586	0.540	7,658	12,436	5,411	10,593
	Zhou C 2019 <sup>46</sup>	0.084	0.580	0.680	219	187	158	88	0.081	0.760	0.430	287	247	90	327
	BAI														
	Adejumo EJ 2019 <sup>42</sup>	58.08	0.784	0.588	78	170	22	119	51.42	0.720	0.653	89	15	34	8
	Gil Llinás M 2019 <sup>49</sup>	30.40	0.752	0.603	1,157	14,895	382	9,807	26.21	0.720	0.624	2954	19,306	1,149	11,633
	Gómez Marcos MA 2019 <sup>50</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Ramírez Vélez R 2019 <sup>54</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Whang H 2017 <sup>44</sup>	30.38	0.530	0.740	39	80	34	28	27.44	0.400	0.870	52	60	77	9
	Zhang J 2018 <sup>45</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Zhou C 2019 <sup>46</sup>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Abbreviation: BMI: body mass index; BRI: body roundness index; FN: false negative value; FP: false positive value; Sen: sensitivity; Spe: specificity; TP: true positive value; TN: true negative value; WC: waist circumference; WHtR: waist-to-hip ratio; WHtR: waist-to-height ratio.




**FIGURE 3** Estimated pooled AUC-SROC in men for BRI (a), BMI (B), WC (C), WHtR (D), ABSI (E) and BAI (F). AUC, area under curve; SROC; summary receiver operating characteristic curve; BAI, body adiposity index; BMI, body mass index; BRI, body roundness index; SE, standard error; WC, waist circumference; WHtR, waist-to-height ratio

power of BMI, WC and WHtR in distinguishing MetS and cardiometabolic risk factors. For MetS, pooled AUCs for WHtR were greater than BMI and WC. Among men in 12 study groups, the difference in AUCs between indices was not statistically significant. However, among women (13 study groups included), BMI was significantly poorer than WHtR (0.72 vs. 0.76;  $p = 0.047$ ). Lo et al<sup>81</sup> published another similar meta-analysis in a paediatric population. In contrast to

the adult population, the authors observed that WC performed better than WHtR in screening for MetS. In this meta-analysis, WHtR and WC were the best predictors of MetS compared with other anthropometric measurements. Pooled AUCs for WHtR were greater than WC for women, men and all subjects, but differences were not statistically significant. However, in the Chinese population, both pooled AUCs were similar, and in the non-Chinese population, pooled AUCs for WC

**FIGURE 4** Estimated pooled AUC-SROC in women for BRI (a), BMI (B), WC (C), WHtR (D), ABSI (E) and BAI (F). ABSI, body shape index; AUC, area under curve; SROC; summary receiver operating characteristic curve; BAI, body adiposity index; BMI, body mass index; BRI, body roundness index; SE, standard error; WC, waist circumference; WHtR, waist-to-height ratio




were statistically non-significantly higher than WHtR. In addition, pooled AUC-SROCs for WHtR were lower than WC for women, men and all subjects, but differences were not statistically significant. Similar results were found for pooled ORs, except for uncategorized pooled ORs for WC, which were inferior to pooled ORs for BRI. The meta-analyses mentioned above<sup>27,81</sup> did not calculate pooled ORs.

The anthropometric measure cut-off points derived from non-Asian populations are not applicable to Asians.<sup>82</sup> Ethnicity is an important modifier in the association between simple anthropometric measures and cardiovascular risk factors, which applies to both men and women.<sup>83</sup> The idea that ethnicity alters the relationship between anthropometric indices and cardiovascular risk factors has been more widely studied with findings that in populations of Chinese origin, raised levels of cardiovascular risk factors occur at lower BMI and WC

values than in European populations.<sup>84–86</sup> Currently, there are no studies comparing BRI values among ethnically different populations. In this meta-analysis, the non-Chinese population pooled AUCs for all anthropometric measurements were better predictors of MetS than for the Chinese population.

Although BRI was not superior to WC and WHtR for determining the presence of MetS, there were no significant differences in the pooled AUCs, ORs or AUC-SROCs for predicting MetS, suggesting that BRI could be used as an alternative obesity measurement in assessing MetS. As Thomas et al.<sup>35</sup> pointed out, the advantages of BRI exceed BMI and WRH because BRI can improve the predictive power of body fat and visceral adipose tissue thus better reflecting health status as a function of the body. The relationship between visceral adipose tissue and MetS is well known.<sup>87</sup> In contrast to the meta-



**FIGURE 5** Estimated pooled AUC-SROC in total population for BRI (a), BMI (b), WC (c), WHR (d), WHtR (e), ABSI (f) and BAI (g). AUC, area under curve; SROC; summary receiver operating characteristic curve; BAI, body adiposity index; BMI, body mass index; BRI, body roundness index; SE, standard error; WC, waist circumference; WHC, waist-to-hip ratio; WHtR, waist-to-height ratio

TABLE 5 Pooled odds ratios of included studies

	BRI			BMI			WC			WHR			WHtR		
	N	OR	(95%CI)	I <sup>2</sup>	N	OR	(95%CI)	I <sup>2</sup>	N	OR	(95%CI)	I <sup>2</sup>	N	OR	(95%CI)
Women	Tertiles (T3)	2 <sup>&amp;</sup>	2.92 (2.01–4.25)	0%	-	-	-	-	-	-	-	-	-	-	-
	Quartiles (Q4)	2 <sup>&amp;</sup>	2.83 (1.02–7.83)	97%	2 <sup>&amp;</sup>	2.42 (0.44–13.23)	98%	2 <sup>&amp;</sup>	3.83 (2.35–6.22)	81%	2 <sup>&amp;</sup>	1.45 (0.27–7.89)	98%	-	-
	Uncategorized	3 <sup>\$</sup>	2.46 (1.94–3.12)	92%	3 <sup>\$</sup>	2.19 (1.31–3.66)	100%	2 <sup>\$</sup>	1.58 (0.79–3.17)	100%	-	-	2 <sup>\$</sup>	3.06 (1.75–5.34)	93%
		2 <sup>#</sup>	2.77 (1.28–5.98)	96%	2 <sup>#</sup>	2.22 (0.66–7.40)	98%	-	-	-	-	-	-	-	-
Men	Quartiles (Q4)	2 <sup>&amp;</sup>	3.95 (1.07–9.40)	95%	2 <sup>&amp;</sup>	3.45 (0.48–24.66)	97%	2 <sup>&amp;</sup>	5.43 (2.26–13.03)	85%	2 <sup>&amp;</sup>	2.08 (0.34–12.83)	96%	-	-
	Uncategorized	3 <sup>\$</sup>	3.23 (1.99–5.27)	96%	3 <sup>\$</sup>	2.66 (1.61–4.40)	99%	2 <sup>\$</sup>	1.66 (0.81–3.41)	1050%	-	-	2 <sup>\$</sup>	3.78 (1.59–8.97)	98%
		2 <sup>#</sup>	3.80 (1.58–9.15)	96%	2 <sup>#</sup>	2.86 (0.68–12.03)	99%	-	-	-	-	-	-	-	-
	Quartiles (Q4)	5 <sup>&amp;</sup>	4.98 (2.31–10.74)	97%	5 <sup>&amp;</sup>	3.92 (1.80–8.53)	97%	5 <sup>&amp;</sup>	6.39 (3.48–11.73)	94%	4 <sup>&amp;</sup>	1.78 (0.78–4.05)	97%	3 <sup>&amp;</sup>	8.76 (4.69–16.35)
Total	Uncategorized	6 <sup>\$</sup>	2.70 (2.36–3.09)	94%	6 <sup>\$</sup>	2.41 (1.74–3.33)	100%	4 <sup>\$</sup>	1.62 (1.08–2.44)	100%	-	-	4 <sup>\$</sup>	3.09 (2.64–3.61)	95%
		4 <sup>#</sup>	3.24 (1.89–5.54)	96%	4 <sup>#</sup>	2.46 (1.62–3.74)	99%	-	-	-	-	-	-	-	-
	ABSI			BAI											
	N	OR	(95%CI)	I <sup>2</sup>	N	OR	(95%CI)	I <sup>2</sup>	N	OR	(95%CI)	I <sup>2</sup>	N	OR	(95%CI)
Women	Tertiles (T3)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Quartiles (Q4)	2 <sup>&amp;</sup>	1.45 (0.95–2.22)	34%	-	-	-	-	-	-	-	-	-	-	-
	Uncategorized	3 <sup>\$</sup>	1.23 (1.07–1.41) <sup>†††</sup>	95%	-	-	-	-	-	-	-	-	-	-	-
		2 <sup>#</sup>	1.37 (0.82–2.28)	93%	-	-	-	-	-	-	-	-	-	-	-
Men	Quartiles (Q4)	2 <sup>&amp;</sup>	1.64 (1.35–1.98)	0%	-	-	-	-	-	-	-	-	-	-	-
	Uncategorized	3 <sup>\$</sup>	1.23 (0.97–1.56) <sup>†††</sup>	94%	-	-	-	-	-	-	-	-	-	-	-
		2 <sup>#</sup>	1.26 (0.77–2.08) <sup>†</sup>	95%	-	-	-	-	-	-	-	-	-	-	-
Total	Quartiles (Q4)	5 <sup>&amp;</sup>	1.79 (1.33–2.40) <sup>†</sup>	73%	-	-	-	-	-	-	-	-	-	-	-
	Uncategorized	6 <sup>\$</sup>	1.21 (1.10–1.34) <sup>†††</sup>	94%	-	-	-	-	-	-	-	-	-	-	-
		4 <sup>#</sup>	1.20 (1.06–1.35) <sup>†††</sup>	92%	-	-	-	-	-	-	-	-	-	-	-

Abbreviations: ABSI, body shape index; BMI, body mass index; BRI, body roundness index; CI, confidence interval; IDF, International Diabetes Federation; WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio.  
<sup>&</sup>Chinese population;  
<sup>\$</sup>Non Chinese population;  
<sup>#</sup>Chinese and non Chinese population. Differences between BRI and BMI, WC, WHR or WHtR:  
<sup>†</sup>*p* < 0.05,  
<sup>††</sup>*p* < 0.01,  
<sup>†††</sup>*p* < 0.001.



analyses of Ashwell M et al.<sup>27</sup> and Lo et al.<sup>81</sup> we did not assess the discriminatory power of anthropometric measurements in distinguishing cardiometabolic risk factors (hypertension, diabetes, dyslipidaemia or CVD). We found that there were few published studies to be able to perform a quality meta-analysis.

This review has several limitations. First, the criterion for identifying MetS involved WC measurement, which may lead to bias despite the high AUC values. In the present review, the definition provided by the IDF is more commonly adopted (five studies), defining elevated WC as a necessary condition for MetS.<sup>88</sup> Other guidelines to identify MetS, including NCEP ATP-III,<sup>4</sup> IDF harmonized<sup>89</sup> and Chinese Diabetes Society<sup>90</sup> criteria, define central obesity as one of the criteria instead of a necessary condition. On the other hand, we used the inverse variance method for pooling the AUCs for each study, and this approach is not the most appropriate for meta-analysis of diagnostic accuracy studies. Actually, the most recommended and rigorous approaches are the SROC model, hierarchical SROC model and bivariate random effects meta-analysis of sensitivities and specificities.<sup>58,91,92</sup> To solve this inconvenient issue, we constructed SROC curves through studies that reported sensitivity and specificity values. Although using hierarchical summary receiver operating characteristic (HSROC) or bivariate random effects models has been advocated,<sup>93</sup> the results provided by these methods are very similar to those obtained by Moses' SROC model.<sup>94</sup> Another limitation is that some studies included in the meta-analysis did not report the AUC/OR of BMI, WC, WHR, WHtR, ABSI or BAI, and the resulting pooled AUCs/ORs did not include the same number of studies for BRI as for the rest of the anthropometric indices. Therefore, comparison bias could be present. A similar issue exists for AUC-SROCs. Finally, this study only included articles written in English or Spanish. Some eligible studies written in other languages might have been missed.

The main strength of the present meta-analysis consists in quantifying the performance of BRI in screening MetS and comparing it with other common and novel anthropometric measures (BMI, WC, WHR, WHtR, ABSI, and BAI). It is the first meta-analysis of the discriminatory power of BRI, highlighting that most of the included studies were published in 2019 (70%).

## 5 | CONCLUSION

This systematic review and meta-analysis is the first to show that BRI is a good predictor of MetS in both sexes in populations of various nationalities and ethnic groups. WC and WHtR offer the best performance when screening MetS, but no significant differences were found with BRI. In contrast, BRI was superior to BMI, WHR, ABSI and BAI in predicting MetS. Finally, pooled ORs showed that increased BRI is associated with increased MetS risk. Further studies should investigate the prospective relationship between BRI and adverse health outcomes in all age groups.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ORCID

Sergio Rico-Martín  <https://orcid.org/0000-0003-4932-1940>

## REFERENCES

1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care*. 2001;24(4):683-689. <https://doi.org/10.2337/diacare.24.4.683>
2. Mente A, Yusuf S, Islam S, et al. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. *J Am Coll Cardiol*. 2010;55(21):2390-2398. <https://doi.org/10.1016/j.jacc.2009.12.053>
3. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. *J Am Coll Cardiol*. 2010;56(14):1113-1132. <https://doi.org/10.1016/j.jacc.2010.05.034>
4. National Institutes of Health. National Heart, Lung and Blood Institute Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106(25):3143-3421.
5. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. *Diabetes Care*. 2011;34(1):216-219. <https://doi.org/10.2337/dc10-0879>
6. Cameron AJ, Magliano DJ, Shaw JE, et al. The influence of hip circumference on the relationship between abdominal obesity and mortality. *Int J Epidemiol*. 2012;41(2):484-494. <https://doi.org/10.1093/ije/dyr198>
7. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. *Lancet (London, England)*. 2005;366(9491):1059-1062. [https://doi.org/10.1016/S0140-6736\(05\)67402-8](https://doi.org/10.1016/S0140-6736(05)67402-8)
8. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham heart study. *Circulation*. 2007;116(1):39-48. <https://doi.org/10.1161/CIRCULATIONAHA.106.675355>
9. Walton C, Lees B, Crook D, Worthington M, Godsland IF, Stevenson JC. Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age. *Am J Med*. 1995;99(5):459-464. [https://doi.org/10.1016/S0002-9343\(99\)80220-4](https://doi.org/10.1016/S0002-9343(99)80220-4)
10. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. *Obes Res*. 1998;6(Suppl 2):S1S-209S.
11. Physical Status: *The Use and Interpretation of Anthropometry*. Report of a WHO Expert Committee. Vol 854. Switzerland; 1995.
12. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. *N Engl J Med*. 2008;359(20):2105-2120. <https://doi.org/10.1056/NEJMoa0801891>
13. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet (London, England)*. 2009;373(9669):1083-1096. [https://doi.org/10.1016/S0140-6736\(09\)60318-4](https://doi.org/10.1016/S0140-6736(09)60318-4)
14. Nuttall FQ. Body mass index: obesity, BMI, and health: a critical review. *Nutr Today*. 2015;50(3):117-128. <https://doi.org/10.1097/NT.0000000000000092>
15. *Obesity: Preventing and Managing the Global Epidemic*. Report of a WHO Consultation. Vol 894. Switzerland; 2000.
16. Aune D, Sen A, Norat T, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. *Circulation*. 2016;133(7):639-649. <https://doi.org/10.1161/CIRCULATIONAHA.115.016801>

17. Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. *Am J Cardiol*. 2015;115(10):1428-1434. <https://doi.org/10.1016/j.amjcard.2015.02.024>
18. Chen H, Deng Y, Li S. Relation of body mass index categories with risk of sudden cardiac death. *Int Heart J*. 2019;60(3):624-630. <https://doi.org/10.1536/ihj.18-155>
19. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*. 2013;309(1):71-82. <https://doi.org/10.1001/jama.2012.113905>
20. Nevill AM, Stewart AD, Olds T, Holder R. Relationship between adiposity and body size reveals limitations of BMI. *Am J Phys Anthropol*. 2006;129(1):151-156. <https://doi.org/10.1002/ajpa.20262>
21. Gomez-Ambrosi J, Silva C, Galofre JC, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. *Int J Obes (Lond)*. 2012;36(2):286-294. <https://doi.org/10.1038/ijo.2011.100>
22. Bigaard J, Frederiksen K, Tjonneland A, et al. Body fat and fat-free mass and all-cause mortality. *Obes Res*. 2004;12(7):1042-1049. <https://doi.org/10.1038/oby.2004.131>
23. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of insulin resistance (EGIR). *Diabet Med*. 1999;16(5):442-443. <https://doi.org/10.1046/j.1464-5491.1999.00059.x>
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (adult treatment panel III). *JAMA*. 2001;285(19):2486-2497. <https://doi.org/10.1001/jama.285.19.2486>
25. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. *Circulation*. 2005;112(17):2735-2752. <https://doi.org/10.1161/CIRCULATIONAHA.105.169404>
26. Lee CMY, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. *J Clin Epidemiol*. 2008;61(7):646-653. <https://doi.org/10.1016/j.jclinepi.2007.08.012>
27. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. *Obes Rev*. 2012;13(3):275-286. <https://doi.org/10.1111/j.1467-789X.2011.00952.x>
28. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. *Eur Heart J*. 2007;28(7):850-856. <https://doi.org/10.1093/eurheartj/ehm026>
29. Nishida C, Ko GT, Kumanyika S. Body fat distribution and non-communicable diseases in populations: overview of the 2008 WHO expert consultation on waist circumference and waist-hip ratio. *Eur J Clin Nutr*. 2010;64(1):2-5. <https://doi.org/10.1038/ejcn.2009.139>
30. Deng G, Yin L, Liu W, et al. Associations of anthropometric adiposity indexes with hypertension risk: a systematic review and meta-analysis including PURE-China. *Medicine (Baltimore)*. 2018;97(48):e13262. <https://doi.org/10.1097/MD.00000000000013262>
31. Seo D-C, Choe S, Torabi MR. Is waist circumference  $\geq 102/88$ cm better than body mass index  $\geq 30$  to predict hypertension and diabetes development regardless of gender, age group, and race/ethnicity? Meta-analysis. *Prev Med (Baltim)*. 2017;97:100-108. <https://doi.org/10.1016/j.ypmed.2017.01.012>
32. Vazquez G, Duval S, Jacobs DRJ, Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. *Epidemiol Rev*. 2007;29:115-128. <https://doi.org/10.1093/epirev/mxm008>
33. Qiao Q, Nyamadorj R. Is the association of type II diabetes with waist circumference or waist-to-hip ratio stronger than that with body mass index? *Eur J Clin Nutr*. 2010;64(1):30-34. <https://doi.org/10.1038/ejcn.2009.93>
34. Kodama S, Horikawa C, Fujihara K, et al. Comparisons of the strength of associations with future type 2 diabetes risk among anthropometric obesity indicators, including waist-to-height ratio: a meta-analysis. *Am J Epidemiol*. 2012;176(11):959-969. <https://doi.org/10.1093/aje/kws172>
35. Thomas DM, Bredlau C, Bosy-Westphal A, et al. Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model. *Obesity (Silver Spring)*. 2013;21(11):2264-2271. <https://doi.org/10.1002/oby.20408>
36. Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. *PLoS ONE*. 2012;7(7):e39504. <https://doi.org/10.1371/journal.pone.0039504>
37. Amato MC, Giordano C, Galia M, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. *Diabetes Care*. 2010;33(4):920-922. <https://doi.org/10.2337/dc09-1825>
38. Bergman RN, Stefanovski D, Buchanan TA, et al. A better index of body adiposity. *Obesity (Silver Spring)*. 2011;19(5):1083-1089. <https://doi.org/10.1038/oby.2011.38>
39. Guerrero-Romero F, Rodriguez-Moran M. Abdominal volume index. An anthropometry-based index for estimation of obesity is strongly related to impaired glucose tolerance and type 2 diabetes mellitus. *Arch Med Res*. 2003;34(5):428-432. [https://doi.org/10.1016/S0188-4409\(03\)00073-0](https://doi.org/10.1016/S0188-4409(03)00073-0)
40. Gomez-Ambrosi J, Silva C, Catalan V, et al. Clinical usefulness of a new equation for estimating body fat. *Diabetes Care*. 2012;35(2):383-388. <https://doi.org/10.2337/dc11-1334>
41. Tian S, Zhang X, Xu Y, Dong H. Feasibility of body roundness index for identifying a clustering of cardiometabolic abnormalities compared to BMI, waist circumference and other anthropometric indices: the China health and nutrition survey, 2008 to 2009. *Medicine (Baltimore)*. 2016;95(34):e4642. <https://doi.org/10.1097/MD.00000000000004642>
42. Adejumo EN, Adejumo AO, Azenabor A, et al. Anthropometric parameter that best predict metabolic syndrome in south West Nigeria. *Diabetes Metab Syndr*. 2019;13(1):48-54. <https://doi.org/10.1016/j.dsx.2018.08.009>
43. Suliga E, Ciesla E, Gluszek-Osuch M, Rogula T, Gluszek S, Koziel D. The usefulness of anthropometric indices to identify the risk of metabolic syndrome. *Nutrients*. 2019;11(11). <https://doi.org/10.3390/nu11112598>
44. Wang H, Liu A, Zhao T, et al. Comparison of anthropometric indices for predicting the risk of metabolic syndrome and its components in Chinese adults: a prospective, longitudinal study. *BMJ Open*. 2017;7(9):e016062. <https://doi.org/10.1136/bmjopen-2017-016062>
45. Zhang J, Zhu W, Qiu L, Huang L, Fang L. Sex- and age-specific optimal anthropometric indices as screening tools for metabolic syndrome in Chinese adults. *Int J Endocrinol*. 2018;2018:1067603. <https://doi.org/10.1155/2018/1067603>
46. Zhou C, Zhan L, Yuan J, Tong X, Peng Y, Zha Y. Comparison of visceral, general and central obesity indices in the prediction of metabolic syndrome in maintenance hemodialysis patients. *Eat Weight Disord*. 2019;1-8. <https://doi.org/10.1007/s40519-019-00678-9>
47. Perona JS, Schmidt Rio-Valle J, Ramirez-Velez R, Correa-Rodriguez M, Fernandez-Aparicio A, Gonzalez-Jimenez E. Waist circumference and abdominal volume index are the strongest anthropometric discriminators of metabolic syndrome in Spanish adolescents. *Eur J Clin Invest*. 2019;49(3):e13060. <https://doi.org/10.1111/eci.13060>



48. Barazzoni R, Gortan Cappellari G, Semolic A, et al. Central adiposity markers, plasma lipid profile and cardiometabolic risk prediction in overweight-obese individuals. *Clin Nutr*. 2019;38(3):1171-1179. <https://doi.org/10.1016/j.clnu.2018.04.014>
49. Llinas MG, Janer PE, Agudo SG, Casquero RG, Gonzalez IC. Usefulness in nursing of different anthropometric and analytical indices to assess the existence of metabolic syndrome with the NCEP ATP III and IDF criteria in Spanish Mediterranean population. *Med Balear*. 2017;32(1):26-34. <https://doi.org/10.3306/MEDICINABALEAR.32.01.26>
50. Gomez-Marcos MA, Gomez-Sanchez L, Patino-Alonso MC, et al. Capacity adiposity indices to identify metabolic syndrome in subjects with intermediate cardiovascular risk (MARK study). *PLoS ONE*. 2019;14(1):e0209992. <https://doi.org/10.1371/journal.pone.0209992>
51. Li G, Wu H-K, Wu X-W, et al. The feasibility of two anthropometric indices to identify metabolic syndrome, insulin resistance and inflammatory factors in obese and overweight adults. *Nutrition*. 2019;57:194-201. <https://doi.org/10.1016/j.nut.2018.05.004>
52. Liu B, Liu B, Wu G, Yin F. Relationship between body-roundness index and metabolic syndrome in type 2 diabetes. *Diabetes Metab Syndr Obes*. 2019;12:931-935. <https://doi.org/10.2147/DMSO.S209964>
53. Liu PJ, Ma F, Lou HP, Zhu YN. Comparison of the ability to identify cardiometabolic risk factors between two new body indices and waist-to-height ratio among Chinese adults with normal BMI and waist circumference. *Public Health Nutr*. 2017;20(6):984-991. <https://doi.org/10.1017/S1368980016003281>
54. Ramirez-Velez R, Perez-Sousa MA, Izquierdo M, et al. Validation of surrogate anthropometric indices in older adults: what is the best indicator of high cardiometabolic risk factor clustering? *Nutrients*. 2019;11(8). <https://doi.org/10.3390/nu11081701>
55. Stefanescu A, Revilla L, Lopez T, Sanchez SE, Williams MA, Gelaye B. Using a body shape index (ABSI) and body roundness index (BRI) to predict risk of metabolic syndrome in Peruvian adults. *J Int Med Res*. 2019;48. <https://doi.org/10.1177/0300060519848854>
56. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151(4):264-269, W64. <https://doi.org/10.7326/0003-4819-151-4-200908180-00135>
57. National Heart Lung and Blood Institute. *Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies*. 2014. <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>
58. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. *Stat Med*. 1993;12(14):1293-1316. <https://doi.org/10.1002/sim.4780121403>
59. Chappell FM, Raab GM, Wardlaw JM. When are summary ROC curves appropriate for diagnostic meta-analyses? *Stat Med*. 2009;28(21):2653-2668. <https://doi.org/10.1002/sim.3631>
60. Swets JA. Measuring the accuracy of diagnostic systems. *Science*. 1988;240(4857):1285-1293. <https://doi.org/10.1126/science.3287615>
61. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-1558. <https://doi.org/10.1002/sim.1186>
62. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634. <https://doi.org/10.1136/bmj.315.7109.629>
63. Santos DA, Silva AM, Matias CN, et al. Utility of novel body indices in predicting fat mass in elite athletes. *Nutrition*. 2015;31(7-8):948-954. <https://doi.org/10.1016/j.nut.2015.02.003>
64. Chang Y, Guo X, Li T, Li S, Guo J, Sun Y. A body shape index and body roundness index: two new body indices to identify left ventricular hypertrophy among rural populations in Northeast China. *Heart Lung Circ*. 2016;25(4):358-364. <https://doi.org/10.1016/j.hlc.2015.08.009>
65. Zhang N, Chang Y, Guo X, Chen Y, Ye N, Sun Y. A body shape index and body roundness index: two new body indices for detecting association between obesity and hyperuricemia in rural area of China. *Eur J Intern Med*. 2016;29:32-36. <https://doi.org/10.1016/j.ejim.2016.01.019>
66. Zhang J, Fang L, Qiu L, Huang L, Zhu W, Yu Y. Comparison of the ability to identify arterial stiffness between two new anthropometric indices and classical obesity indices in Chinese adults. *Atherosclerosis*. 2017;263:263-271. <https://doi.org/10.1016/j.atherosclerosis.2017.06.031>
67. Gomez-Sanchez L, Garcia-Ortiz L, Patino-Alonso MC, et al. Adiposity measures and arterial stiffness in primary care: the MARK prospective observational study. *BMJ Open*. 2017;7(9):e016422. <https://doi.org/10.1136/bmjopen-2017-016422>
68. Haraguchi N, Koyama T, Kuriyama N, et al. Assessment of anthropometric indices other than BMI to evaluate arterial stiffness. *Hypertens Res*. 2019;42(10):1599-1605. <https://doi.org/10.1038/s41440-019-0264-0>
69. Li G, Yao T, Wu X-W, et al. Novel and traditional anthropometric indices for identifying arterial stiffness in overweight and obese adults. *Clin Nutr*. March 2019;39(3):893-900. <https://doi.org/10.1016/j.clnu.2019.03.029>
70. Maessen MFH, Eijssvogels TMH, Verheggen RJHM, Hopman MTE, Verbeek ALM, de Vegt F. Entering a new era of body indices: the feasibility of a body shape index and body roundness index to identify cardiovascular health status. *PLoS ONE*. 2014;9(9):e107212. <https://doi.org/10.1371/journal.pone.0107212>
71. Chung W, Park JH, Chung HS, Yu JM, Kim DS, Moon S. Utility of the Z-score of log-transformed a body shape index (LBSIZ) in the assessment for sarcopenic obesity and cardiovascular disease risk in the United States. *Sci Rep*. 2019;9(1):9292. <https://doi.org/10.1038/s41598-019-45717-8>
72. Chang Y, Guo X, Chen Y, et al. A body shape index and body roundness index: two new body indices to identify diabetes mellitus among rural populations in Northeast China. *BMC Public Health*. 2015;15:794. <https://doi.org/10.1186/s12889-015-2150-2>
73. Zhao Q, Zhang K, Li Y, et al. Capacity of a body shape index and body roundness index to identify diabetes mellitus in Han Chinese people in Northeast China: a cross-sectional study. *Diabet Med*. 2018;35(11):1580-1587. <https://doi.org/10.1111/dme.13787>
74. Yang J, Wang F, Wang J, et al. Using different anthropometric indices to assess prediction ability of type 2 diabetes in elderly population: a 5 year prospective study. *BMC Geriatr*. 2018;18(1):218. <https://doi.org/10.1186/s12877-018-0912-2>
75. Wang Z, He S, Chen X. Capacity of different anthropometric measures to predict diabetes in a Chinese population in Southwest China: a 15-year prospective study. *Diabet Med*. June 2019;36(10):1261-1267. <https://doi.org/10.1111/dme.14055>
76. Zhang K, Zhao Q, Li Y, et al. Feasibility of anthropometric indices to identify dyslipidemia among adults in Jilin Province: a cross-sectional study. *Lipids Health Dis*. 2018;17(1):16. <https://doi.org/10.1186/s12944-017-0648-6>
77. Zaid M, Ameer F, Munir R, et al. Anthropometric and metabolic indices in assessment of type and severity of dyslipidemia. *J Physiol Anthropol*. 2017;36(1):19. <https://doi.org/10.1186/s40101-017-0134-x>
78. Mathur N, Rai S, Sujith N, Gayatri O. Newer v/s classical anthropometric indices as a screening tool for dyslipidemia in healthy young adults. *J Clin Diagn Res*. 2019;13(4):BC04-BC07. <https://doi.org/10.7860/JCDR/2019/40827.12799>
79. Chang Y, Guo X, Guo L, Li Z, Li Y, Sun Y. The feasibility of two new anthropometric indices to identify hypertension in rural China: a

- cross-sectional study. *Medicine (Baltimore)*. 2016;95(44):e5301. <https://doi.org/10.1097/MD.0000000000005301>
80. Choi JR, Ahn SV, Kim JY, et al. Comparison of various anthropometric indices for the identification of a predictor of incident hypertension: the ARIRANG study. *J Hum Hypertens*. 2018;32(4):294-300. <https://doi.org/10.1038/s41371-018-0043-4>
  81. Lo K, Wong M, Khalechelam P, Tam W. Waist-to-height ratio, body mass index and waist circumference for screening paediatric cardiometabolic risk factors: a meta-analysis. *Obes Rev*. 2016;17(12):1258-1275. <https://doi.org/10.1111/obr.12456>
  82. Halder S, Chia SC, Henry CJ. Body composition in Asians and Caucasians: comparative analyses and influences on Cardiometabolic outcomes. *Adv Food Nutr Res*. 2015;75:97-154. <https://doi.org/10.1016/b.safnr.2015.07.001>
  83. Lear SA, Toma M, Birmingham CL, Frohlich JJ. Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. *Metabolism*. 2003;52(10):1295-1301. [https://doi.org/10.1016/s0026-0495\(03\)00196-3](https://doi.org/10.1016/s0026-0495(03)00196-3)
  84. Razak F, Anand SS, Shannon H, et al. Defining obesity cut points in a multiethnic population. *Circulation*. 2007;115(16):2111-2118. <https://doi.org/10.1161/CIRCULATIONAHA.106.635011>
  85. Patel S, Unwin N, Bhopal R, et al. A comparison of proxy measures of abdominal obesity in Chinese, European and south Asian adults. *Diabet Med*. 1999;16(10):853-860. <https://doi.org/10.1046/j.1464-5491.1999.00163.x>
  86. Ko GT, Chan JC, Woo J, et al. Simple anthropometric indexes and cardiovascular risk factors in Chinese. *Int J Obes Relat Metab Disord*. 1997;21(11):995-1001. <https://doi.org/10.1038/sj.ijo.0800508>
  87. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. *Endocr Rev*. 2000;21(6):697-738. <https://doi.org/10.1210/edrv.21.6.0415>
  88. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. *Diabet Med*. 2006;23(5):469-480. <https://doi.org/10.1111/j.1464-5491.2006.01858.x>
  89. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009;120(16):1640-1645. <https://doi.org/10.1161/CIRCULATIONAHA.109.192644>
  90. Weng J, Ji L, Jia W, et al. Standards of care for type 2 diabetes in China. *Diabetes Metab Res Rev*. 2016;32(5):442-458. <https://doi.org/10.1002/dmrr.2827>
  91. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. *Stat Med*. 2001;20(19):2865-2884. <https://doi.org/10.1002/sim.942>
  92. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin Epidemiol*. 2005;58(10):982-990. <https://doi.org/10.1016/j.jclinepi.2005.02.022>
  93. Harbord RM, Whiting P, Sterne JAC, et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. *J Clin Epidemiol*. 2008;61(11):1095-1103. <https://doi.org/10.1016/j.jclinepi.2007.09.013>
  94. Simel DL, Bossuyt PMM. Differences between univariate and bivariate models for summarizing diagnostic accuracy may not be large. *J Clin Epidemiol*. 2009;62(12):1292-1300. <https://doi.org/10.1016/j.jclinepi.2009.02.007>

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Rico-Martín S, Calderón-García JF, Sánchez-Rey P, Franco-Antonio C, Martínez Álvarez M, Sánchez Muñoz-Torrero JF. Effectiveness of body roundness index in predicting metabolic syndrome: A systematic review and meta-analysis. *Obesity Reviews*. 2020;21:e13023. <https://doi.org/10.1111/obr.13023>